Atomo DiagnosticsASX:AT1 Days Payable is 96.63 as of Dec. 2025, which is 40% above its 10-year median of 68.91. The stock has 4 warning signs investors should review. Among 796 Medical Devices & Instruments companies, Atomo Diagnostics ranks better than 73.24% on this metric.
The historical rank and industry rank for Atomo Diagnostics's Days Payable or its related term are showing as below:
ASX:AT1'
s Days Payable Range Over the Past 10 Years
Min: 23.3 Med: 68.91 Max: 156.21
Current: 127.44
During the past 6 years, Atomo Diagnostics's highest Days Payable was 156.21. The lowest was 23.30. And the median was 68.91.
ASX:AT1's Days Payable is ranked better than 73.24% of 796
companies
in the Medical Devices & Instruments industry
Industry Median: 68.14
vs ASX:AT1: 127.44
Atomo Diagnostics's Days Payable
declined
from Dec. 2024 (97.30) to Dec. 2025 (96.63).
It may suggest that Atomo Diagnosticsaccelerated paying its suppliers.
Atomo Diagnostics Days Payable Related Terms
Atomo Diagnostics Days Payable Historical Data
* Premium members only.
The historical data trend for Atomo Diagnostics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Atomo Diagnostics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atomo Diagnostics Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Atomo Diagnostics's Days Payable distribution charts can be found below:
* The bar in red indicates where Atomo Diagnostics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Atomo Diagnostics's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Atomo Diagnostics (ASX:AT1) has a Days Payable of 96.63 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Atomo Diagnostics and its competitors. This is 40% above median its historical median of 68.91. Over the past decade, Atomo Diagnostics' Days Payable has ranged from 23.30 to 156.21. According to the industry distribution chart, Atomo Diagnostics ranks #213 out of 796 companies in the Medical Devices & Instruments industry, placing it in the top 26.8%.
Is Atomo Diagnostics' Days Payable too high?
Atomo Diagnostics' current Days Payable of 96.63 is 40% above median its 10-year median of 68.91. Over the past 10 years, this metric has ranged from a low of 23.30 to a high of 156.21. The Medical Devices & Instruments industry median Days Payable is 68.14. Atomo Diagnostics' value of 96.63 is 41.8% above this industry median. Based on the distribution chart, Atomo Diagnostics ranks #213 out of 796 companies in the Medical Devices & Instruments industry, which is above the industry midpoint.
How does Atomo Diagnostics' Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Atomo Diagnostics ranks #213 out of 796 companies for Days Payable. This puts Atomo Diagnostics in the upper half of its industry. The industry median Days Payable is 68.14. Atomo Diagnostics' value of 96.63 is 41.8% above this benchmark. Historically, Atomo Diagnostics' own Days Payable has ranged from 23.30 to 156.21 over the past decade. While the company's 10-year median is 68.91 vs. the industry median of 68.14, Atomo Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.14, based on 796 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Atomo Diagnostics's current Days Payable of 96.63 is 41.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Atomo Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Atomo Diagnostics's current Days Payable is 96.63, which is 40% above median its own 10-year median of 68.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atomo Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Atomo Diagnostics (ASX:AT1) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.02 — trading 15% below its estimated fair value. The current Days Payable is 96.63, which is 40% above median its 10-year median of 68.91 and 41.8% above the Medical Devices & Instruments industry median of 68.14. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Atomo Diagnostics (ASX:AT1), the current Days Payable is 96.63 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Atomo Diagnostics Ltd is an Australian medical device design innovator and original equipment manufacturing company. The company is engaged in the development and sale of medical devices. The company develops point-of-care devices for rapid diagnostic testing. The company offers AtomoRapid RDT Platform with devices including Galileo, Pascal, Curie, and Elion. The firm operates in a single segment, medical device research and development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AT1 has been successfully added to your 